Research Article

You have free access to this content

Differences in the frequencies of K-ras c12–13 genotypes by gender and pathologic phenotypes in colorectal tumors measured using the allele discrimination method†‡

  1. Lihui Chow1,
  2. Peng-Chan Lin2,
  3. Jeffrey S. Chang1,
  4. Pei-Yi Chu3,
  5. Pao-Kung Lee1,
  6. Shan-Na Chen1,
  7. Ying-Min Cheng1,
  8. Jenq-Chang Lee2,
  9. Jang-Yang Chang1,
  10. Tsang-Wu Liu1,*

Article first published online: 25 AUG 2011

DOI: 10.1002/em.20673

Issue

Environmental and Molecular Mutagenesis

Environmental and Molecular Mutagenesis

Volume 53, Issue 1, pages 22–31, January 2012

Additional Information

How to Cite

Chow, L., Lin, P.-C., Chang, J. S., Chu, P.-Y., Lee, P.-K., Chen, S.-N., Cheng, Y.-M., Lee, J.-C., Chang, J.-Y. and Liu, T.-W. (2012), Differences in the frequencies of K-ras c12–13 genotypes by gender and pathologic phenotypes in colorectal tumors measured using the allele discrimination method. Environ. Mol. Mutagen., 53: 22–31. doi: 10.1002/em.20673

Author Information

  1. 1

    National Institute of Cancer Research, National Health Research Institutes, Zhunan, Taiwan

  2. 2

    Department of Internal Medicine, National Cheng-Kung University Hospital, Tainan, Taiwan

  3. 3

    Department of Pathology, St. Martin De Porres Hospital, Chiayi, Taiwan

*35 Keyan Road, Zhunan, Miaoli County 350, Taiwan

  1. †

    None of the authors have a conflict of interest to disclose.

  2. ‡

    Dr. Tsang-Wu Liu approved and supported this project as the primary investigator of the Tumor Marker Laboratory of the National Institute of Cancer Research. Dr. Jang-Yang Chang initiated this project as the director of the National Institute of Cancer Research. Dr. Jeng-Chang Lee coordinated specimen collection as the head of the department of surgery of National Cheng Kung University. Dr. Peng-Chan Lin conducted patient enrollment as a senior hemato-oncologist in the Department of Internal Medicine of National Cheng Kung University. Dr. Jeffrey S. Chang performed statistical analyses and edited this manuscript. Dr. Pei-Yi Chu is the pathologist who reviewed this manuscript. Pao-Kung Lee worked on the early method development and result comparison. Shan-Na Chen contributed experimental support. Ying-Min Cheng modified and continued the assay. Dr. Lihui Chow designed the assay, analyzed results, and drafted the manuscript.

Publication History

  1. Issue published online: 5 JAN 2012
  2. Article first published online: 25 AUG 2011
  3. Manuscript Accepted: 13 JUL 2011
  4. Manuscript Revised: 12 JUL 2011
  5. Manuscript Received: 4 NOV 2010

Funded by

  • Department of Health of Taiwan. Grant Number: DOH99-TD-C-111-004

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (2075K)

REFERENCES

  • Abubaker J,Bavi P,Al-Haqawi W,Sultana M,Al-Harbi S,Al-Sanea N,Abduljabbar A,Ashari LH,Alhomoud S,Al-Dayel F,Uddin S,Al-Kuraya KS. 2009. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol 219: 435–445.
    Direct Link:
  • Akagi K,Uchibori R,Yamaguchi K,Kurosawa K,Tanaka Y,Kozu T. 2007. Characterization of a novel oncogenic K-ras mutation in colon cancer. Biochem Biophys Res Commun 352: 728–732.
  • Al-Mulla F,Going JJ,Sowden ET,Winter A,Pickford IR,Birnie GD. 1998. Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. J Pathol 185: 130–138.
    Direct Link:
  • Amado RG,Wolf M,Peeters M,Van Cutsem E,Siena S,Freeman DJ,Juan T,Sikorski R,Suggs S,Radinsky R,Patterson SD,Chang DD. 2008. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626–1634.
  • Andreyev HJ,Norman AR,Cunningham D,Oates JR,Clarke PA. 1998. Kirsten ras mutations in patients with colorectal cancer: The multicenter “RASCAL” study. J Natl Cancer Inst 90: 675–684.
  • Baisse B,Bouzourene H,Saraga EP,Bosman FT,Benhattar J. 2001. Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma. Int J Cancer 93: 346–352.
    Direct Link:
  • Bazan V,Migliavacca M,Zanna I,Tubiolo C,Grassi N,Latteri MA,La Farina M,Albanese I,Dardanoni G,Salerno S,Tomasino RM,Labianca R,Gebbia N,Russo A. 2002. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 13: 1438–1446.
  • Breivik J,Meling GI,Spurkland A,Rognum TO,Gaudernack G. 1994. K-ras mutation in colorectal cancer: Relations to patient age, sex and tumour location. Br J Cancer 69: 367–371.
  • Brink M,de Goeij AF,Weijenberg MP,Roemen GM,Lentjes MH,Pachen MM,Smits KM,de Bruine AP,Goldbohm RA,van den Brandt PA. 2003. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 24: 703–710.
  • Chang YS,Yeh KT,Chang TJ,Chai C,Lu HC,Hsu NC,Chang JG. 2009. Fast simultaneous detection of K-RAS mutations in colorectal cancer. BMC Cancer 9: 179.
  • Do H,Krypuy M,Mitchell PL,Fox SB,Dobrovic A. 2008. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. BMC Cancer 8: 142.
  • Edkins S,O'Meara S,Parker A,Stevens C,Reis M,Jones S,Greenman C,Davies H,Dalgliesh G,Forbes S,Hunter C,Smith R,Stephens P,Goldstraw P,Nicholson A,Chan TL,Velculescu VE,Yuen ST,Leung SY,Stratton MR,Futreal PA. 2006. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 5: 928–932.
  • Gallegos Ruiz MI,Floor K,Rijmen F,Grunberg K,Rodriguez JA,Giaccone G. 2007. EGFR and K-ras mutation analysis in non-small cell lung cancer: Comparison of paraffin embedded versus frozen specimens. Cell Oncol 29: 257–264.
  • Kobunai T,Watanabe T,Yamamoto Y,Eshima K. 2010. The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: A comparison between direct sequencing and real-time PCR. Biochem Biophys Res Commun 395: 158–162.
  • Lee JC,Wang ST,Lai MD,Lin YJ,Yang HB. 1996. K-ras gene mutation is a useful predictor of the survival of early stage colorectal cancers. Anticancer Res 16: 3839–3844.
  • Lefferts JA,Tsongalis GJ,Suriawinata AA,Funkhouser WK,Ladanyi M,Nowak JA,Pipas JM. 2010. KRAS mutation detection: A new look at an old gene. Clin Chem 56: 698–701.
  • Li CF,Huang WW,Wu JM,Yu SC,Hu TH,Uen YH,Tian YF,Lin CN,Lu D,Fang FM,Huang HY. 2008. Heat shock protein 90 overexpression independently predicts inferior disease-free survival with differential expression of the alpha and beta isoforms in gastrointestinal stromal tumors. Clin Cancer Res 14: 7822–7831.
  • Losi L,Baisse B,Bouzourene H,Benhattar J. 2005. Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis 26: 916–922.
  • Marchetti A,Gasparini G. 2009. K-ras mutations and cetuximab in colorectal cancer. N Engl J Med 360: 833–834. Author reply 835–836.
  • Miyakura Y,Sugano K,Fukayama N,Konishi F,Nagai H. 2002. Concurrent mutations of K-ras oncogene at codons 12 and 22 in colon cancer. Jpn J Clin Oncol 32: 219–221.
  • Neumann J,Zeindl-Eberhart E,Kirchner T,Jung A. 2009. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract 205: 858–862.
  • Ohnishi T,Tomita N,Monden T,Ohue M,Yana I,Takami K,Yamamoto H,Yagyu T,Kikkawa N,Shimano T,Monden M. 1997. A detailed analysis of the role of K-ras gene mutation in the progression of colorectal adenoma. Br J Cancer 75: 341–347.
  • Pajkos G,Kiss I,Sandor J,Ember I,Kishazi P. 2000. The prognostic value of the presence of mutations at the codons 12, 13, 61 of K-ras oncogene in colorectal cancer. Anticancer Res 20: 1695–1701.
  • Palmirotta RSA,Formica V,Ludovici G,Del Monte G,Roselli M,Guadagni F. 2009. A novel K-ras mutation in colorectal cancer. A case report and literature review. Anticancer Res 29: 3369–3374.
  • Poehlmann AKD,Meyer F,Lippert H,Roessner A,Schneider-Stock R. 2007. K-ras mutation detection in colorectal cancer using pyrosequencing technique. Pathol Res Pract 203: 489–497.
  • Rouleau E,Spyratos F,Dieumegard B,Guinebretiere JM,Lidereau R,Bieche I. 2008. KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: The need for a more precise definition. Br J Cancer 99: 2100.
  • Samowitz WS,Curtin K,Schaffer D,Robertson M,Leppert M,Slattery ML. 2000. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: A population-based study. Cancer Epidemiol Biomarkers Prev 9: 1193–1197.
  • Simi L,Pratesi N,Vignoli M,Sestini R,Cianchi F,Valanzano R,Nobili S,Mini E,Pazzagli M,Orlando C. 2008. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 130: 247–253.
  • Slattery ML,Curtin K,Anderson K,Ma KN,Edwards S,Leppert M,Potter J,Schaffer D,Samowitz WS. 2000. Associations between dietary intake and Ki-ras mutations in colon tumors: A population-based study. Cancer Res 60: 6935–6941.
  • Souglakos J,Philips J,Wang R,Marwah S,Silver M,Tzardi M,Silver J,Ogino S,Hooshmand S,Kwak E,Freed E,Meyerhardt JA,Saridaki Z,Georgoulias V,Finkelstein D,Fuchs CS,Kulke MH,Shivdasani RA. 2009. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br J Cancer 101: 465–472.
  • Span M,Moerkerk PT,De Goeij AF,Arends JW. 1996. A detailed analysis of K-ras point mutations in relation to tumor progression and survival in colorectal cancer patients. Int J Cancer (Pred Oncol) 69: 241–245.
    Direct Link:
  • Toyooka S,Tsukuda K,Ouchida M,Tanino M,Inaki Y,Kobayashi K,Yano M,Soh J,Kobatake T,Shimizu N,Shimizu K. 2003. Detection of codon 61 point mutations of the K-ras gene in lung and colorectal cancers by enriched PCR. Oncol Rep 10: 1455–1459.
  • Tsukuda K,Tanino M,Soga H,Shimizu N,Shimizu K. 2000. A novel activating mutation of the K-ras gene in human primary colon adenocarcinoma. Biochem Biophys Res Commun 278: 653–658.
  • Vogelstein B,Fearon ER,Kern SE,Hamilton SR,Preisinger AC,Nakamura Y,White R. 1989. Allelotype of colorectal carcinomas. Science 244: 207–211.
  • Wang JY,Hsieh JS,Chen FM,Yeh CS,Alexandersen K,Huang TJ,Chen D,Lin SR. 2003. High frequency of activated K-ras codon 15 mutant in colorectal carcinomas from Taiwanese patients. Int J Cancer 107: 387–393.
    Direct Link:
  • Wang JY,Hsieh JS,Lu CY,Yu FJ,Wu JY,Chen FM,Huang CJ,Lin SR. 2007. The differentially mutational spectra of the APC, K-ras, and p53 genes in sporadic colorectal cancers from Taiwanese patients. Hepatogastroenterology 54: 2259–2265.
  • Wong R,Cunningham D. 2008. Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor antibodies. J Clin Oncol 26: 5668–5670.
View Full Article (HTML) Get PDF (2075K)